Related Experiment Video
Updated: Jan 18, 2026
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Survival and Surrogate Biomarkers in Interventional Oncology Trials: Pitfalls, Challenges, and Future Directions
Ana P Gonzalez1, Adam Swersky1, Riad Salem2
1Department of Radiology, Section of Interventional Radiology, Northwestern Feinberg School of Medicine, 676 N. St. Clair, Suite 800, Chicago, IL, USA.
Introduction:
Interventional oncology (IO) is a key component of multidisciplinary cancer care, delivering minimally invasive therapies with safety and efficacy comparable to or surpassing conventional approaches. As IO enters a transformative era, the field must continue demonstrating value within the greater world of oncology, particularly through the study and application of surrogate endpoints.
Surrogate Endpoint Definitions And Validation Criteria:
A central requirement for advancing IO is the rigorous evaluation of treatment outcomes through translational research. Surrogate endpoints, including imaging-based criteria and serum biomarkers, expedite therapeutic assessment, yet their validity as predictors of clinical benefit remains under scrutiny.
Regulatory And Methodological Challenges:
Experience from prior IO studies underscores the complex interplay between surrogate endpoints, overall survival, and quality of life metrics. Variable regulatory acceptance, incomplete validation, and inconsistencies in endpoint definition and reporting continue to challenge their adoption.
Primary Liver Tumors:
In hepatocellular carcinoma (HCC), surrogate endpoints have informed treatment evaluation; however, their predictive strength and reproducibility remain variable across studies.
Secondary Liver Malignancies:
Applications in metastatic liver disease similarly rely on imaging and serum-based surrogates, though performance and reliability remain heterogeneous.
Limitations:
Uncertainty persists regarding the ability of surrogate endpoints to reliably predict durable clinical outcomes, limiting their broader applicability.
Future Directions:
Advancing IO will require the integration of modern trial methodologies, synthetic control arms, radiomics, and artificial intelligence to strengthen surrogate endpoint validation and facilitate broader clinical and regulatory acceptance.
Conclusions:
By embracing its characteristically innovative spirit while maintaining a critical lens on data interpretation, the IO community can not only advance therapeutic development but also reinforce its indispensability in oncology. The beginning of a new quarter century brings a pivotal juncture, with an opportunity to reimagine IO's trajectory bridging technical ingenuity with the nuanced demands of modern cancer care.
Insights
Interventional oncology (IO) uses surrogate endpoints to assess cancer treatments, but their reliability in predicting patient benefit needs improvement. Future research will integrate advanced methods to enhance validation and acceptance of these crucial markers.
Area of Science:
- Interventional Oncology (IO)
- Translational Cancer Research
- Clinical Trial Methodology
Background:
- Interventional oncology (IO) is integral to multidisciplinary cancer care, offering minimally invasive therapies.
- The field is evolving, necessitating robust demonstration of value, particularly through surrogate endpoints.
- Surrogate endpoints, such as imaging and biomarkers, expedite treatment assessment but require rigorous validation.
Purpose of the Study:
- To evaluate the role and challenges of surrogate endpoints in interventional oncology.
- To explore the complexities of surrogate endpoint validation and their prediction of clinical benefit.
- To identify future directions for strengthening surrogate endpoint utility in IO research.
Main Methods:
- Review of existing interventional oncology studies and their use of surrogate endpoints.
- Analysis of regulatory and methodological challenges impacting surrogate endpoint adoption.
- Examination of surrogate endpoint application in specific cancers like hepatocellular carcinoma and liver metastases.
Main Results:
- Surrogate endpoints in IO expedite therapeutic assessment but their validity as predictors of clinical benefit remains under scrutiny.
- Inconsistent validation, definition, and reporting challenge the adoption of surrogate endpoints.
- Performance and reliability of surrogate endpoints are heterogeneous across studies, particularly in liver cancers.
Conclusions:
- Uncertainty persists regarding the ability of surrogate endpoints to reliably predict durable clinical outcomes.
- Advancing IO requires integrating modern trial methodologies, synthetic control arms, radiomics, and AI for surrogate endpoint validation.
- The IO community must balance innovation with critical data interpretation to reinforce its role in oncology.
Related Concept Videos
01:21Cancer Survival Analysis
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...